Track ETON and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Eton Pharmaceuticals Inc
21925 W. Field Parkway, Deer Park, IL, United States, 60010-7278
IPO
2018
Employees
44
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q3 20252-2
0
Q2 20253-3
0
2-quarter cumulative
5 sells0 buys
Analyst Ratings
1 analysts covering
Buy100%recommend buy
Buy
1
Hold
0
Sell
0